TY - JOUR
T1 - Pruritus in primary myelofibrosis
T2 - management options in the era of JAK inhibitors
AU - Vaa, Brianna E.
AU - Tefferi, Ayalew
AU - Gangat, Naseema
AU - Pardanani, Animesh
AU - Lasho, Terra L.
AU - Finke, Christy M.
AU - Wolanskyj, Alexandra P.
N1 - Publisher Copyright:
© 2016, Springer-Verlag Berlin Heidelberg.
PY - 2016/6/1
Y1 - 2016/6/1
N2 - Primary myelofibrosis (PMF)-associated pruritus is often severe and requires treatment. Fifty-one patients with bone marrow-proven PMF with associated pruritus were identified from a primary cohort of patients with PMF (n = 566) seen at our institution. We conducted a retrospective review of the clinical characteristics, severity of pruritus, type of treatment, and response of these patients. Thirty-two out of 51 patients (63 %) reported severe PMF-associated pruritus and required a total of 108 treatment episodes, with complete response (CR), partial response (PR) and no response (NR) observed in 22, 23, and 55 % of episodes, respectively. The most common treatment categories included JAK inhibitors (n = 19), anti-depressants (n = 18), and antihistamines (n = 17). Highest CR rates were observed in patients treated with a JAK inhibitor (53 %) and immunomodulatory drugs (IMiDS (50 %)). Emerging targeted therapies may result in better symptom control and higher response rates in patients suffering from severe PMF-associated pruritus.
AB - Primary myelofibrosis (PMF)-associated pruritus is often severe and requires treatment. Fifty-one patients with bone marrow-proven PMF with associated pruritus were identified from a primary cohort of patients with PMF (n = 566) seen at our institution. We conducted a retrospective review of the clinical characteristics, severity of pruritus, type of treatment, and response of these patients. Thirty-two out of 51 patients (63 %) reported severe PMF-associated pruritus and required a total of 108 treatment episodes, with complete response (CR), partial response (PR) and no response (NR) observed in 22, 23, and 55 % of episodes, respectively. The most common treatment categories included JAK inhibitors (n = 19), anti-depressants (n = 18), and antihistamines (n = 17). Highest CR rates were observed in patients treated with a JAK inhibitor (53 %) and immunomodulatory drugs (IMiDS (50 %)). Emerging targeted therapies may result in better symptom control and higher response rates in patients suffering from severe PMF-associated pruritus.
KW - JAK inhibitors
KW - Primary myelofibrosis
KW - Pruritus
KW - Treatment options
UR - http://www.scopus.com/inward/record.url?scp=84964199908&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84964199908&partnerID=8YFLogxK
U2 - 10.1007/s00277-016-2674-2
DO - 10.1007/s00277-016-2674-2
M3 - Article
C2 - 27106700
AN - SCOPUS:84964199908
SN - 0939-5555
VL - 95
SP - 1185
EP - 1189
JO - Annals of hematology
JF - Annals of hematology
IS - 7
ER -